Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Risky Is Vaxart?

TheMotleyFool

0 0

Vaxart (NASDAQ: VXRT) brought investors high hopes over the past several months. Imagine a vaccine without the jab: That's Vaxart's specialty. The clinical-stage biotech company is developing oral vaccines for a variety of viruses -- including SARS-CoV-2, the virus that causes COVID-19.

The company's shares soared more than 1,500% last year as Vaxart's investigational coronavirus vaccine made it through preclinical studies and began a human trial. Then, one specific element in the biotech company's phase 1 trial report disappointed investors, and the stock tumbled a massive 58% in one trading session on Feb. 3.

Now the question is about risk. How risky is it to invest in, or hold on to, Vaxart shares right now?

Source Fool.com

Like: 0

VXRT

Share